| P50 | author | Richard D. Smith | Q7325058 |
| | Henrik Zetterberg | Q6252048 |
| | Dietmar Fuchs | Q38801487 |
| | Magnus Gisslén | Q90302675 |
| | Thomas E Angel | Q93154621 |
| | Lars Hagberg | Q97650293 |
| | Serena Spudich | Q114411897 |
| | Richard W Price | Q124366832 |
| | Julia Peterson | Q124366838 |
| | Jon M Jacobs | Q124366849 |
| | Joseph N. Brown | Q124366850 |
| P2860 | cites work | SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease | Q21144971 |
| | HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors | Q24631745 |
| | Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment | Q24814874 |
| | Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010 | Q27690715 |
| | CD4+ count-guided interruption of antiretroviral treatment | Q29619489 |
| | Amyloid and tau cerebrospinal fluid biomarkers in HIV infection | Q33520347 |
| | Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection | Q33933507 |
| | HIV-1 replication in the central nervous system occurs in two distinct cell types. | Q34050421 |
| | Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 |
| | Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies | Q34139859 |
| | HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study | Q34370880 |
| | Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. | Q34402201 |
| | Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort | Q34497788 |
| | Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells. | Q39985237 |
| | HIV-1 viral load and clinical outcome: review of recent studies. | Q41694976 |
| | Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection | Q41978842 |
| | Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection | Q43477829 |
| | Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment | Q43551611 |
| | The AIDS dementia complex: I. Clinical features | Q43769670 |
| | Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. | Q44028578 |
| | Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia | Q44253971 |
| | Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection | Q44936423 |
| | Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain | Q45759163 |
| | Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group | Q45759166 |
| | Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection | Q46520858 |
| | Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study | Q47249301 |
| | Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication | Q47672132 |
| | Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors | Q48244275 |
| | Cognitive disorders in HIV-infected patients: are they HIV-related? | Q48329945 |
| | Cerebrospinal fluid markers that predict SIV CNS disease | Q48957436 |
| | HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment | Q34644242 |
| | Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection | Q34740804 |
| | Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects | Q34792090 |
| | Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden | Q35164448 |
| | Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy | Q35532868 |
| | Incidence of post-dural puncture headache in research volunteers | Q35552718 |
| | Updated research nosology for HIV-associated neurocognitive disorders | Q35755761 |
| | The cerebrospinal fluid proteome in HIV infection: change associated with disease severity | Q35965332 |
| | Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection | Q36060674 |
| | Central nervous system viral invasion and inflammation during acute HIV infection | Q36376213 |
| | HIV-1 pathogenesis: the virus | Q36526530 |
| | Mechanisms of HIV-1 neurotropism | Q36536166 |
| | Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection | Q36796560 |
| | Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy | Q36854127 |
| | The HIV-1 env protein: a coat of many colors | Q36856091 |
| | Biomarkers of HIV-1 CNS infection and injury | Q36984776 |
| | Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers | Q37015519 |
| | Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy | Q37066971 |
| | The role of HIV in serious diseases other than AIDS. | Q37186467 |
| | Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection | Q37351669 |
| | Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load | Q37436136 |
| | CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease | Q37465068 |
| | Antiretroviral drug treatment of CNS HIV-1 infection | Q37967355 |
| | HIV and inflammation: mechanisms and consequences | Q38005046 |
| | Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection | Q38429930 |
| | CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. | Q38433078 |
| | Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy | Q38460449 |
| | Changing incidence of central nervous system diseases in the EuroSIDA cohort | Q38479888 |
| | HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia | Q39483826 |
| | The AIDS dementia complex | Q39535506 |
| | The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex | Q39628230 |
| | Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes | Q39713596 |
| | Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial | Q50457244 |
| | Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. | Q50553161 |
| | Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. | Q53333738 |
| | Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF | Q55952248 |
| | Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy | Q57176735 |
| | Cognitive dysfunction in HIV patients despite long-standing suppression of viremia | Q58074796 |
| | Elevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV-associated neurological disorders | Q58480109 |
| | Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force | Q70181586 |
| | Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group | Q70706038 |
| | Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment | Q73064672 |
| | Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex | Q74532087 |
| | Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection | Q78066974 |
| | Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex | Q80306158 |
| | Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection | Q81037707 |
| | Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex | Q82029827 |
| | Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array | Q82206160 |
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| | biomarker | Q864574 |
| | AIDS dementia complex | Q3435504 |
| P304 | page(s) | 1147-1158 | |
| P577 | publication date | 2013-08-13 | |
| | 2013-12-01 | |
| P1433 | published in | Journal of Neuroimmune Pharmacology | Q6295645 |
| P1476 | title | Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection | |
| P478 | volume | 8 | |